logo

Clinical Trial Results

Share

pharmaup-feb14.jpg The following are some of today's top gainers in the pharma/biotech sector.

pharma-042617_13feb19.jpg The following are some of today's top gainers in the pharma/biotech sector.

pharmaup-feb12.jpg The following are some of today's top gainers in the pharma/biotech sector.

pharmaup-feb11.jpg The following are some of today's top gainers in the pharma/biotech sector.

MacroGenics, Inc. (MGNX) announced positive results from SOPHIA, the company's Phase 3 clinical study of margetuximab in HER2-positive metastatic breast cancer patients. MacroGenics anticipates submitting a Biologics License Application (BLA) to the U.S. Food and Drug Administration in the second half...

pharmaup-feb04.jpg The following are some of today's top gainers in the pharma/biotech sector.

pharmaup-jan31.jpg The following are some of today's top gainers in the pharma/biotech sector.

pharmaup-jan30.jpg The following are some of today's top gainers in the pharma/biotech sector.

pharmaup-jan29.jpg The following are some of today's top gainers in the pharma/biotech sector.

pharmadown-jan28.jpg The following are some of the pharma/biotech stocks that posted the biggest percentage decline today.

pharmaup-jan28.jpg The following are some of today's top gainers in the pharma/biotech sector.

pharmadown-jan22.jpg The following are some of the pharma/biotech stocks that posted the biggest percentage decline today.

pharmaup-jan22.jpg The following are some of today's top gainers in the pharma/biotech sector.

Eli Lilly and Company (LLY) said that a late-stage trial of a treatment for sarcoma did not meet the primary endpoints. It is suspending promotion of lartruvo. It expects to incur a charge of $70 million - $90 million pre-tax or $0.10 per share in the first quarter. In addition, the company expects the...

pharmaup-jan17.jpg The following are some of today's top gainers in the pharma/biotech sector.

Follow RTT